{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-019045","form_type":"8-K","ticker":"OVID","cik":"0001636651","company_name":"Ovid Therapeutics Inc.","filed_at":"2026-03-18T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.707674+00:00","generated_at":"2026-05-15T09:53:49.295742+00:00","sec_items":["1.01","2.02","3.02","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Ovid Therapeutics raises $60M PIPE, reports positive OV329 data, expands indications, and clears OV4071 for Phase 1","bullets":["$60M PIPE: 19.15M shares at $2.01 and pre-funded warrants for 10.7M shares; closing expected March 19, 2026.","OV329 7 mg cohort: no treatment-related adverse events; Phase 2 for focal onset seizures planned for Q2 2026.","OV329 development expanded to tuberous sclerosis complex seizures (Q4 2026) and infantile spasms (2027).","OV4071 (oral KCC2 activator) received HREC/TGA approval; Phase 1 in Australia starts Q2 2026.","Cash $90.4M at Dec 31, 2025; net loss FY2025 $17.4M ($0.23/share); Series A warrants could add $53.9M."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-019045","json":"https://secwatch.observer/filing/0001628280-26-019045.json","markdown":"https://secwatch.observer/filing/0001628280-26-019045.md","text":"https://secwatch.observer/filing/0001628280-26-019045.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1636651/000162828026019045/0001628280-26-019045-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1636651/000162828026019045/ovid-20260318.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T09:53:49.295742+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4380d323ffed329722a7e2d41b0ba7340dd67c0d","claim":"Ovid Therapeutics Inc. entered into Securities Purchase Agreement with the purchasers named therein valued at $60.0 million (effective 2026-03-17).","evidence_excerpt":"On March 17, 2026, Ovid Therapeutics Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with the purchasers named therein (the “Investors”), pursuant to which the Company agreed to issue and sell an aggregate of 19,154,321 shares (the “Shares”) of its common stock, par value $0.001 per share (“Common Stock”), at a purchase price of $2.01 per share","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1636651/000162828026019045/0001628280-26-019045-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"the purchasers named therein"},{"label":"Value","value":"$60.0 million"},{"label":"Effective","value":"2026-03-17"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}